Khadeeja Mohamed Selected Research

tafenoquine

1/2022	Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial.
1/2019	Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
1/2019	Randomized Placebo-Controlled Trial Evaluating the Ophthalmic Safety of Single-Dose Tafenoquine in Healthy Volunteers.
1/2019	Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
1/2018	Application of the Stable Isotope Label Approach in Clinical Development-Supporting Dissolution Specifications for a Commercial Tablet Product with Tafenoquine, a Long Half-life Compound.
9/2017	Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers.
1/2017	A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria.
12/2016	Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects.
9/2014	Tafenoquine at therapeutic concentrations does not prolong Fridericia-corrected QT interval in healthy subjects.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Khadeeja Mohamed Research Topics

Disease

9	Vivax Malaria 01/2022 - 09/2014
2	Body Weight (Weight, Body) 01/2022 - 12/2016
2	Infections 01/2022 - 01/2019
2	Glucosephosphate Dehydrogenase Deficiency 09/2017 - 12/2016
1	Vomiting 01/2022
1	Parasitemia 01/2019
1	Hemolysis 09/2017
1	Fever (Fevers) 01/2017
1	Visceral Leishmaniasis (Kala Azar) 06/2011

Drug/Important Bio-Agent (IBA)

9	tafenoquineIBA 01/2022 - 09/2014
3	Glucosephosphate Dehydrogenase (Glucose 6 Phosphate Dehydrogenase)IBA 01/2022 - 09/2017
3	Primaquine FDA Link 01/2019 - 01/2017
3	8-aminoquinolineIBA 01/2018 - 06/2011
1	TabletsIBA 01/2022
1	EnzymesIBA 09/2017
1	Chloroquine (Aralen)FDA LinkGeneric 01/2017
1	Pharmaceutical PreparationsIBA 12/2016
1	Lumefantrine Drug Combination Artemether (Coartem)FDA Link 12/2016
1	piperaquineIBA 12/2016
1	artenimol (dihydroartemisinin)IBA 12/2016

Therapy/Procedure

4	Secondary Prevention 01/2022 - 09/2014
1	Therapeutics 01/2019